Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
Resolve Therapeutics Announces RSLV-132 Significantly Reduces Fatigue in Phase II Study of Patients with Sjögren’s Syndrome
Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology
Resolve Therapeutics To Present Phase II Data on Lead Product Candidate RSLV-132 at the 2019 EULAR European Congress of Rheumatology
Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus
Resolve Therapeutics Announces Publication of Clinical Data Demonstrating the Role of Circulating RNA in Systemic Lupus Erythematosus
Resolve to Present Data on Lupus Studies at International Rheumatology Conference
Resolve to Present Data on Lupus Studies at International Rheumatology Conference
Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study
Resolve Announces Positive Clinical Data from RSLV-132 Lupus Study
Resolve Initiates RSLV-132 Clinical Studies
Resolve Initiates RSLV-132 Clinical Studies
Takeda and Resolve Therapeutics Enter Autoimmune Partnership
Takeda and Resolve Therapeutics Enter Autoimmune Partnership
Resolve Therapeutics Raises $5.8 Million in Private Financing
Resolve Therapeutics Raises $5.8 Million in Private Financing
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired
How to Make Money in Biotech With No Hope of Going Public, Slim Odds of Getting Acquired